entinostat (SNDX-275) - Kyowa Hakko Kirin, Syndax
KHK2375: Completion of P2 trial (NCT03291886) for advanced or recurrent hormone receptor-positive breast cancer in November 2021 (Kyowa Hakko Kirin Pharma) - Aug 2, 2019 - Q2 2019 Results 
Trial completion date
https://ir.kyowakirin.com/en/library/earnings.html
 
Aug 2, 2019
 
 
ccb54cd6-ea44-4592-9cc2-43ef79f76f7a.jpg